Program
PF-07054894
Its studies are mostly in Colitis, Ulcerative, led by Pfizer.
Furthest: phase 1, since May 12, 20203 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 30 open or running | phase 1since May 12, 2020 | May 12, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 12, 2020First study: phase 1 study in HealthyFirst studyNCT04388878 · 84 enrolled · Belgium
- Sep 17, 2022Phase 1 study in Colitis, UlcerativeNCT05549323 · 44 enrolled · United States, Germany, Poland
- May 5, 2025Phase 1 study in HealthyNCT07009353 · 10 enrolled · Netherlands
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07009353Healthy · Netherlands | 1 | Completed | Aug 20, 2025 | 10 |
| NCT05549323Colitis, Ulcerative · United States, Germany, Poland | 1 | Terminated | Nov 11, 2025 | 44 |
| NCT04388878Healthy · Belgium | 1 | Completed | Jun 21, 2022 | 84 |
How it is read
Names in the registry
- “PF-07054894”, 4 entries
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.